- Home
- MEGL vs ALZN Comparison
MEGL vs ALZN Comparison
Compare MEGL & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGL
- ALZN
- Stock Information
- Founded
- MEGL 2016
- ALZN 2016
- Country
- MEGL Hong Kong
- ALZN United States
- Employees
- MEGL N/A
- ALZN N/A
- Industry
- MEGL Finance: Consumer Services
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- MEGL Finance
- ALZN Health Care
- Exchange
- MEGL Nasdaq
- ALZN Nasdaq
- Market Cap
- MEGL 6.8M
- ALZN 7.5M
- IPO Year
- MEGL 2022
- ALZN 2021
- Fundamental
- Price
- MEGL $1.41
- ALZN $2.34
- Analyst Decision
- MEGL
- ALZN Strong Buy
- Analyst Count
- MEGL 0
- ALZN 1
- Target Price
- MEGL N/A
- ALZN $42.00
- AVG Volume (30 Days)
- MEGL 35.5K
- ALZN 130.9K
- Earning Date
- MEGL 12-11-2025
- ALZN 12-11-2025
- Dividend Yield
- MEGL N/A
- ALZN N/A
- EPS Growth
- MEGL N/A
- ALZN N/A
- EPS
- MEGL N/A
- ALZN N/A
- Revenue
- MEGL $1,296,394.00
- ALZN N/A
- Revenue This Year
- MEGL N/A
- ALZN N/A
- Revenue Next Year
- MEGL N/A
- ALZN N/A
- P/E Ratio
- MEGL N/A
- ALZN N/A
- Revenue Growth
- MEGL N/A
- ALZN N/A
- 52 Week Low
- MEGL $1.02
- ALZN $2.06
- 52 Week High
- MEGL $5.52
- ALZN $15.30
- Technical
- Relative Strength Index (RSI)
- MEGL 41.13
- ALZN 47.97
- Support Level
- MEGL $1.41
- ALZN $2.27
- Resistance Level
- MEGL $1.49
- ALZN $2.43
- Average True Range (ATR)
- MEGL 0.09
- ALZN 0.16
- MACD
- MEGL -0.02
- ALZN 0.00
- Stochastic Oscillator
- MEGL 0.04
- ALZN 41.92
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.